艾沙康唑对实验性隐球菌性脑膜炎的治疗有效。
Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.
作者信息
Wiederhold Nathan P, Kovanda Laura, Najvar Laura K, Bocanegra Rosie, Olivo Marcos, Kirkpatrick William R, Patterson Thomas F
机构信息
University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
出版信息
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5600-3. doi: 10.1128/AAC.00229-16. Print 2016 Sep.
Abstract
We evaluated the efficacy of isavuconazole against cryptococcal meningitis. Treatment with either oral isavuconazole (120 mg/kg and 240 mg/kg twice a day [BID]) or fluconazole as the positive control significantly improved survival in mice infected intracranially with either Cryptococcus neoformans USC1597 or H99 and significantly reduced brain fungal burdens for both isolates. Concentrations of isavuconazole in plasma and brain tissue also demonstrated that the greatest improvements in survival and fungal burden were associated with elevated exposures.
摘要
我们评估了艾沙康唑对新型隐球菌性脑膜炎的疗效。口服艾沙康唑（120mg/kg和240mg/kg，每日两次[BID]）或氟康唑作为阳性对照进行治疗，显著提高了颅内感染新型隐球菌USC1597或H99的小鼠的存活率，并显著降低了两种分离株的脑真菌负荷。血浆和脑组织中艾沙康唑的浓度也表明，存活率和真菌负荷的最大改善与暴露量升高有关。
相似文献
1
Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5600-3. doi: 10.1128/AAC.00229-16. Print 2016 Sep.
2
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
Antimicrob Agents Chemother. 2009 Jan;53(1):309-11. doi: 10.1128/AAC.01216-08. Epub 2008 Oct 27.
3
Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy.
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01315-18. Print 2018 Nov.
4
Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis.
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00546-19. Print 2019 Sep.
5
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
Antimicrob Agents Chemother. 2008 Apr;52(4):1580-2. doi: 10.1128/AAC.01384-07. Epub 2008 Jan 22.
6
The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis.
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.01071-18. Print 2018 Sep.
7
Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746.
Med Mycol. 2000 Jun;38(3):221-4. doi: 10.1080/mmy.38.3.221.224.
8
Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.
Antimicrob Agents Chemother. 2013 Feb;57(2):745-50. doi: 10.1128/AAC.01624-12. Epub 2012 Nov 19.
9
Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.
Antimicrob Agents Chemother. 2008 Aug;52(8):2959-61. doi: 10.1128/AAC.00646-08. Epub 2008 Jun 16.
10
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.
Antimicrob Agents Chemother. 2015 Jan;59(1):666-8. doi: 10.1128/AAC.04055-14. Epub 2014 Oct 13.
引用本文的文献
1
Advancing cryptococcal treatment: The role of nanoparticles in mitigating antifungal resistance.
Curr Res Microb Sci. 2024 Nov 22;8:100323. doi: 10.1016/j.crmicr.2024.100323. eCollection 2025.
2
Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosis .
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0045923. doi: 10.1128/aac.00459-23. Epub 2023 Sep 26.
3
Methods for Antifungal Susceptibility Testing of the / Complex: Strengths and Limitations.
J Fungi (Basel). 2023 May 5;9(5):542. doi: 10.3390/jof9050542.
4
Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosis .
bioRxiv. 2023 Apr 10:2023.04.10.536237. doi: 10.1101/2023.04.10.536237.
5
Clinical and pathological characterization of Central Nervous System cryptococcosis in an experimental mouse model of stereotaxic intracerebral infection.
PLoS Negl Trop Dis. 2023 Jan 19;17(1):e0011068. doi: 10.1371/journal.pntd.0011068. eCollection 2023 Jan.
6
The Role of Isavuconazonium Sulphate for the Treatment of Blastomycosis: A Case Series and Antifungal Susceptibility.
Open Forum Infect Dis. 2022 Apr 27;9(7):ofac220. doi: 10.1093/ofid/ofac220. eCollection 2022 Jul.
7
Successful Treatment of Cryptococcal Meningitis and Cryptococcoma with Isavuconazole in a Patient Living with HIV.
J Fungi (Basel). 2021 May 28;7(6):425. doi: 10.3390/jof7060425.
8
Isavuconazole-Animal Data and Clinical Data.
J Fungi (Basel). 2020 Oct 6;6(4):209. doi: 10.3390/jof6040209.
9
Isavuconazole Therapy of Disseminated and Encephalic Infection in an Acute Myeloid Leukemia Patient Treated with Midostaurin.
Mediterr J Hematol Infect Dis. 2020 May 1;12(1):e2020026. doi: 10.4084/MJHID.2020.026. eCollection 2020.
10
Extrapolating Antifungal Animal Data to Humans - Is it reliable?
Curr Fungal Infect Rep. 2020 Mar;14(1):50-62. doi: 10.1007/s12281-020-00370-x. Epub 2020 Jan 16.
本文引用的文献
1
Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4568-76. doi: 10.1128/AAC.00514-16. Print 2016 Aug.
2
Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.
Clin Infect Dis. 2016 Aug 1;63(3):356-62. doi: 10.1093/cid/ciw305. Epub 2016 May 11.
3
Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Diagn Microbiol Infect Dis. 2015 Aug;82(4):303-13. doi: 10.1016/j.diagmicrobio.2015.04.008. Epub 2015 Apr 29.
4
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.
Antimicrob Agents Chemother. 2015 May;59(5):2855-66. doi: 10.1128/AAC.04907-14. Epub 2015 Mar 9.
5
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.
Antimicrob Agents Chemother. 2015 Jan;59(1):666-8. doi: 10.1128/AAC.04055-14. Epub 2014 Oct 13.
6
Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.
Antimicrob Agents Chemother. 2013 Dec;57(12):6284-9. doi: 10.1128/AAC.01355-13. Epub 2013 Oct 7.
7
Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.
Antimicrob Agents Chemother. 2013 Nov;57(11):5642-8. doi: 10.1128/AAC.01354-13. Epub 2013 Sep 3.
8
Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.
J Clin Microbiol. 2013 Sep;51(9):3090-3. doi: 10.1128/JCM.01190-13. Epub 2013 Jun 26.
9
In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.
J Clin Microbiol. 2013 Aug;51(8):2608-16. doi: 10.1128/JCM.00863-13. Epub 2013 Jun 5.
10
Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.
Antimicrob Agents Chemother. 2013 Feb;57(2):745-50. doi: 10.1128/AAC.01624-12. Epub 2012 Nov 19.
Zotero 插件